Angiogenesis: an indicator of metastasis in non-small cell lung cancer invading the thoracic inlet - PubMed (original) (raw)
Angiogenesis: an indicator of metastasis in non-small cell lung cancer invading the thoracic inlet
P Macchiarini et al. Ann Thorac Surg. 1994 Jun.
Abstract
We have attempted to identify a biologic rationale for the local aggressiveness and late treatment failure of resected non-small cell lung cancer involving the thoracic inlet. Tumor specimens from 28 patients who underwent a new transcervical approach were analyzed for the expression of tumor proliferative activity, suppressor-gene p53, intratumoral and peritumoral blood vessel invasion by tumor cells, the presence and degree of angiogenesis (induction of new capillaries and venules), and other biologic variables. Eighty-nine percent of the neoplasms were moderately or poorly differentiated, 89% expressed either an intermediate or high proliferative activity, 39% showed p53 aberrations, 71% exhibited induction of angiogenesis, and 39% had tumors that were positive for blood vessel invasion. With a median follow-up time of 3.5 years (range, 8 to 145+ months), the overall projected 5-year survival was 29% and the median disease-free interval was 23 months. Results of univariate and multivariate analysis of survival and the disease-free interval identified the degree of angiogenesis (density less than 1 versus more than 1 and number of neovessels less than 6 versus more than 6) as the only independent and significant predictors of the disease-free interval. Patients whose tumor showed a density of angiogenesis of 1 or greater and a number of neovessels of 6 or greater faced a significantly (p = 0.0001) higher relative risk of suffering systemic recurrence of their primary tumor than did their low-risk counterparts. Results demonstrate that angiogenesis significantly correlates with late treatment failure (metastasis), and this is acquired at a critical density and number of vessels.
Similar articles
- BRCA1-associated protein 1 deficiency in lung adenocarcinoma predicts poor outcome and increased tumor invasion.
Shen C, Wang Y, Wei P, Du X. Shen C, et al. BMC Cancer. 2016 Aug 23;16(1):670. doi: 10.1186/s12885-016-2670-x. BMC Cancer. 2016. PMID: 27553041 Free PMC article. - Plasma DNA, microsatellite alterations, and p53 tumor mutations are associated with disease-free survival in radically resected non-small cell lung cancer patients: a study of the perugia multidisciplinary team for thoracic oncology.
Ludovini V, Pistola L, Gregorc V, Floriani I, Rulli E, Piattoni S, Di Carlo L, Semeraro A, Darwish S, Tofanetti FR, Stocchi L, Mihaylova Z, Bellezza G, Del Sordo R, Daddi G, Crinò L, Tonato M. Ludovini V, et al. J Thorac Oncol. 2008 Apr;3(4):365-73. doi: 10.1097/JTO.0b013e318168c7d0. J Thorac Oncol. 2008. PMID: 18379354 - [Clinicopathological study on primary lung cancer--immunohistochemical expression of p53 suppressor gene and bcl-2 oncogene in relation to prognosis].
Irie K, Ishida H, Furukawa T, Koyanagi K, Miyamoto Y. Irie K, et al. Rinsho Byori. 1996 Jan;44(1):32-41. Rinsho Byori. 1996. PMID: 8691638 Review. Japanese. - Influence of anterior tumor location on survival after resection of lung cancer invading the thoracic inlet (Pancoast tumors).
Tsitsias T, Yasufuku K, Pierre A, Leighl N, Cho J, Waddell TK, Darling G, Cypel M, Donahoe L, Yeung J, Keshavjee S, de Perrot M. Tsitsias T, et al. J Thorac Cardiovasc Surg. 2023 May;165(5):1710-1719.e3. doi: 10.1016/j.jtcvs.2022.10.033. Epub 2022 Nov 2. J Thorac Cardiovasc Surg. 2023. PMID: 36481062 Review.
Cited by
- Nintedanib in Combination With Chemotherapy in the Treatment of Non-small Cell Lung Cancer: A Systematic Review and Meta-Analysis.
Alhadeethi A, Adel Awwad S, Abed M, Amin AM, Aboelkhier MM, Yassin MNA, Morsi MH, Kashbour MO. Alhadeethi A, et al. Cureus. 2024 Feb 7;16(2):e53812. doi: 10.7759/cureus.53812. eCollection 2024 Feb. Cureus. 2024. PMID: 38465177 Free PMC article. Review. - Preoperative immunonutrition regulates tumor infiltrative lymphocytes and increases tumor angiogenesis in gastric cancer patients.
Peker KD, Ozkanli SS, Akyuz C, Uzun O, Yasar NF, Duman M, Yol S. Peker KD, et al. Arch Med Sci. 2017 Oct;13(6):1365-1372. doi: 10.5114/aoms.2016.60054. Epub 2016 May 19. Arch Med Sci. 2017. PMID: 29181067 Free PMC article. - Role of VEGF-A and its receptors in sporadic and MEN2-associated pheochromocytoma.
Ferreira CV, Siqueira DR, Romitti M, Ceolin L, Brasil BA, Meurer L, Capp C, Maia AL. Ferreira CV, et al. Int J Mol Sci. 2014 Mar 26;15(4):5323-36. doi: 10.3390/ijms15045323. Int J Mol Sci. 2014. PMID: 24675699 Free PMC article. - CREB3L1 is a metastasis suppressor that represses expression of genes regulating metastasis, invasion, and angiogenesis.
Mellor P, Deibert L, Calvert B, Bonham K, Carlsen SA, Anderson DH. Mellor P, et al. Mol Cell Biol. 2013 Dec;33(24):4985-95. doi: 10.1128/MCB.00959-13. Epub 2013 Oct 14. Mol Cell Biol. 2013. PMID: 24126059 Free PMC article. - Angiogenin and vascular endothelial growth factor expression in lungs of lung cancer patients.
Rozman A, Silar M, Kosnik M. Rozman A, et al. Radiol Oncol. 2012 Dec;46(4):354-9. doi: 10.2478/v10019-012-0031-1. Epub 2012 Nov 9. Radiol Oncol. 2012. PMID: 23412843 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous